Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078, China.
Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Inflammopharmacology. 2023 Apr;31(2):611-631. doi: 10.1007/s10787-023-01176-2. Epub 2023 Mar 9.
Neurological symptoms are prevalent in both the acute and post-acute phases of coronavirus disease 2019 (COVID-19), and they are becoming a major concern for the prognosis of COVID-19 patients. Accumulation evidence has suggested that metal ion disorders occur in the central nervous system (CNS) of COVID-19 patients. Metal ions participate in the development, metabolism, redox and neurotransmitter transmission in the CNS and are tightly regulated by metal ion channels. COVID-19 infection causes neurological metal disorders and metal ion channels abnormal switching, subsequently resulting in neuroinflammation, oxidative stress, excitotoxicity, neuronal cell death, and eventually eliciting a series of COVID-19-induced neurological symptoms. Therefore, metal homeostasis-related signaling pathways are emerging as promising therapeutic targets for mitigating COVID-19-induced neurological symptoms. This review provides a summary for the latest advances in research related to the physiological and pathophysiological functions of metal ions and metal ion channels, as well as their role in COVID-19-induced neurological symptoms. In addition, currently available modulators of metal ions and their channels are also discussed. Collectively, the current work offers a few recommendations according to published reports and in-depth reflections to ameliorate COVID-19-induced neurological symptoms. Further studies need to focus on the crosstalk and interactions between different metal ions and their channels. Simultaneous pharmacological intervention of two or more metal signaling pathway disorders may provide clinical advantages in treating COVID-19-induced neurological symptoms.
神经系统症状在 2019 冠状病毒病(COVID-19)的急性期和恢复期都很常见,并且正在成为 COVID-19 患者预后的一个主要关注点。越来越多的证据表明,金属离子紊乱发生在 COVID-19 患者的中枢神经系统(CNS)中。金属离子参与 CNS 的发育、代谢、氧化还原和神经递质传递,并且受到金属离子通道的严格调节。COVID-19 感染导致神经系统金属紊乱和金属离子通道异常切换,随后导致神经炎症、氧化应激、兴奋毒性、神经元细胞死亡,最终引发一系列 COVID-19 引起的神经系统症状。因此,与金属稳态相关的信号通路正成为缓解 COVID-19 引起的神经系统症状的有前途的治疗靶点。这篇综述总结了关于金属离子和金属离子通道的生理和病理生理功能及其在 COVID-19 引起的神经系统症状中的作用的最新研究进展。此外,还讨论了目前可用的金属离子及其通道调节剂。总的来说,根据已发表的报告和深入的思考,目前的工作提出了一些建议来改善 COVID-19 引起的神经系统症状。进一步的研究需要集中在不同金属离子及其通道之间的串扰和相互作用上。同时干预两种或多种金属信号通路紊乱可能在治疗 COVID-19 引起的神经系统症状方面具有临床优势。